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School of Medicine, Albuquerque, New MexicoABSTRACT Deregulation of epidermal growth factor receptor (EGFR) signaling has been correlated with the development of a
variety of human carcinomas. EGF-induced receptor dimerization and consequent trans- auto-phosphorylation are among the
earliest events in signal transduction. Binding of EGF is thought to induce a conformational change that consequently unfolds an
ectodomain loop required for dimerization indirectly. It may also induce important allosteric changes in the cytoplasmic domain.
Despite extensive knowledge on the physiological activation of EGFR, the effect of targeted therapies on receptor conformation
is not known and this particular aspect of receptor function, which can potentially be influenced by drug treatment, may in part
explain the heterogeneous clinical response among cancer patients. Here, we used Fo¨rster resonance energy transfer/fluores-
cence lifetime imaging microscopy (FRET/FLIM) combined with two-color single-molecule tracking to study the effect of ATP-
competitive small molecule tyrosine kinase inhibitors (TKIs) and phosphatase-based manipulation of EGFR phosphorylation on
live cells. The distribution of dimer on-times was fitted to a monoexponential to extract dimer off-rates (koff). Our data show that
pretreatment with gefitinib (active conformation binder) stabilizes the EGFR ligand-bound homodimer. Overexpression of
EGFR-specific DEP-1 phosphatase was also found to have a stabilizing effect on the homodimer. No significant difference in
the koff of the dimer could be detected when an anti-EGFR antibody (425 Snap single-chain variable fragment) that allows
for dimerization of ligand-bound receptors, but not phosphorylation, was used. These results suggest that both the conformation
of the extracellular domain and phosphorylation status of the receptor are involved in modulating the stability of the dimer. The
relative fractions of these two EGFR subpopulations (interacting versus free) were obtained by a fractional-intensity analysis of
ensemble FRET/FLIM images. Our combined imaging approach showed that both the fraction and affinity (surrogate of confor-
mation at a single-molecule level) increased after gefitinib pretreatment or DEP-1 phosphatase overexpression. Using an EGFR
mutation (I706Q, V948R) that perturbs the ability of EGFR to dimerize intracellularly, we showed that a modest drug-induced
increase in the fraction/stability of the EGFR homodimer may have a significant biological impact on the tumor cell’s proliferation
potential.INTRODUCTIONThe human epidermal growth factor receptor (EGFR, also
known as HER or ErbB) family comprises four receptor
tyrosine kinases (TKs) that play a key role in signaling in
normal (1,2) as well as carcinogenic cells of various organs
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0006-3495/15/03/1013/14 $2.00frequently associated with overexpression of HER family
members and amplification of downstream signaling path-
ways. In particular, EGFR (HER1 or ErbB1) overexpression
has been linked to the progression of many human cancers,
including head and neck, breast, and non-small-cell lung
cancers (4,5), making it a primary candidate for targeted
therapies.
EGFR is a 170 kDa transmembrane protein with intrinsic
TK activity. Ligand binding to the extracellular region
(domains I–IV) triggers conformational changes that expose
domain II of EGFR, which unfolds into a dimerization arm
(6). The newly accessible molecular interface allows for
typical homo- or hetero-oligomeric interactions of the re-
ceptors across the entire family. This process is thought tohttp://dx.doi.org/10.1016/j.bpj.2015.01.005
1014 Coban et al.drive the allosteric activation of the intracellular TK domain
(TKD) and trans autophosphorylation of several cyto-
plasmic tyrosine residues within the dimer. These phosphor-
ylated residues serve as docking sites for various adaptor
molecules that are responsible for the propagation of down-
stream signaling (7).
A significant understanding of these conformation-depen-
dent activation mechanisms has been facilitated by structure
determination using x-ray crystallography (8–11) combined
with site-directed mutagenesis (6,12–17) and pharmacolog-
ical inhibition approaches (18–20). Crystallographic struc-
tures have shown an asymmetric, ligand-induced, active
kinase dimer that forms through the C-lobe of one kinase
molecule docking to the N-lobe of another kinase molecule
(12,13). The juxtamembrane (JM) domain and C-tail seg-
ments, which flank the N- and C-terminal ends of the kinase
domain, respectively, were also identified to regulate the
activation process (12,13,21–23).
Single-molecule fluorescence imaging and spectroscopy
methods, which can directly visualize the EGFR homo-
dimer association/dissociation in real time (24–31), can pro-
vide invaluable insights into the static structures of various
conformational states and their functional consequences.
Experiments performed at the individual-molecule level
allow us to observe the kinetic pathways of EGFR mole-
cules in monomeric, dimeric, and different oligomeric states
that are difficult to detect in ensemble measurements. Other
investigators and we (32–34) have previously reported on
the conformational changes induced by the anti-EGFR TK
inhibitors (TKIs) erlotinib and gefitinib on EGFR. These
recent findings suggest that TKI-bound receptors may
exhibit different dissociation rates (koff) as a consequence
of cytoplasmic phosphorylation downmodulation. Inside-
out signaling is known to occur and may account for the sta-
bilizing effect of type I inhibitors (which are thought to bind
only the active EGFR-TKD conformation) such as erlotinib
and gefitinib on the EGFR ectodomain (ECD) dimers (35).
Various computational models have been developed to
elucidate the full mechanism of the ErbB conformational
changes that occur in response to growth factor stimulation
or TKI treatment (36–43). Although there are some mathe-
matical models of EGFR signaling that incorporate the
single-molecule dynamics of EGFR interactions (44), ad-
vances are still limited by the scarcity of experimental
data on the binding kinetics (kon and koff) of intact receptors
in live cells.
In this study, we used two-color, single-molecule imaging
to follow the dissociation of EGFR dimers on the plasma
membrane of epithelial breast cancer cells in real time and
to characterize changes in the dissociation rate constant as
a function of the receptor’s cytoplasmic phosphorylation
state. Similar dissociation constants were determined for
EGF and 425 Snap scFv ligand-bound dimers regardless
of whether or not the ligand was causing EGFR activation.
EGFR homodimers were stabilized by pretreatment withBiophysical Journal 108(5) 1013–1026TKIs or in the presence of overexpressed density-enhanced
phosphatase-1 (DEP-1). We recently showed that the trans-
membrane receptor protein phosphatase DEP-1 interacts
with the intracellular portion of EGFR (45). Besides
changes in single-molecule binding kinetics, ensemble Fo¨r-
ster resonance energy transfer/fluorescence lifetime imag-
ing microscopy (FRET/FLIM) measurements showed an
increase in the fraction of receptor undergoing dimerization
in cells that were pretreated with TKI. Interactions among
individual monomers were also probed via single-pair
FRET (spFRET). This study establishes the cytoplasmic
tyrosine phosphorylation as a modulator of EGFR dimeriza-
tion and oligomerization.MATERIALS AND METHODS
Cell culture and transfection
Cultured epithelial breast cancer cells (HCC1954) (46) were grown in
RPMI 1640 (Sigma-Aldrich, UK) supplemented with 10% fetal bovine
serum, 20 mM glutamine, and 1% penicillin/streptomycin (Invitrogen,
Carlsbad, CA) under 5% CO2 at 37
C. The plasmid encoding GFP-tagged
DEP-1 phosphatase (wild-type (WT) and phosphatase-incompetent DEP-1
cs mutant) was constructed and expressed as reported previously (45). Tran-
sient phosphatase expression in HCC1954 cells was achieved by transfec-
tion of 1 mg of plasmid DNA using fugene HD (Promega, UK) according
to the manufacturer’s protocol. The WT and I706Q V948R ErbB1 mutant
plasmids were constructed and expressed as described previously (47).
Transient transfection was achieved using the same protocol as for the phos-
phatase expression.Antibody fragments, ligands, and inhibitors
425(scFv) is derived from the mouse monoclonal antibody 425 directed
against EGFR. The 425 Snap (scFv) expression vector was kindly provided
by S. Barth (RWTHAachen University, Aachen, Germany). Production and
labeling of the 425 Snap (scFv) fusion protein (scFv in short) was per-
formed as described elsewhere (48). The antibody was fluorescently labeled
with either Snap-Alexa Fluor 546 or Snap-Alexa Fluor 647 (New England
Biolabs, UK) with a labeling stoichiometry of 0.3 and 0.9 dye molecules/
protein, respectively. Monoclonal mouse F4 antibody raised against the
cytoplasmic domain of human EGFR was obtained from Cancer Research
UK. The F4 antibody was amino labeled in-house with Alexa Fluor 546
(dye/protein ¼ 1.1) and DyLight 649 (dye/protein ¼ 3.1). Alexa Fluor
555 D38-B1 (anti-EGFR) and Alexa Fluor 647 D38-B1 (anti-EGFR) mono-
clonal antibodies raised against the intracellular part of the receptor were
purchased from New England Biolabs, UK. EGF (Peprotech, NJ) was
labeled (Cambridge Research Biochemicals, UK) with Alexa Fluor 546
and Atto 647 monoreactive esters (Life Technologies, UK) with dye/
protein ¼ ~1. The TKIs lapatinib and gefitinib were purchased from
VWR International (UK).Cell proliferation
Cells were plated at 0.5  104 cells/well in a 96-well plate. The next day,
they were transfected with 0.3 mg WT and I706Q V948R ErbB1 plasmids
per well. Gefitinib treatment was applied at 24 h after transfection at vari-
able concentrations between 0 and 30 mM. Cell viability was quantified at
96 h after gefitinib treatment using an Alamar Blue assay (Life Sciences).
The Alamar Blue fluorescence readout was measured on a fluorescence
plate reader and the dose-response curves of gefitinib treatment were
determined.
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Measurements in live cells
HCC1954 cells were seeded onto borosilicate glass-bottomed chambers at
an appropriate number to reach ~60–70% confluence within 24 h. After in-
cubation in Optimem reduced serum media (Gibco, UK) for 2 h at 37C un-
der 5% CO2, the cells were treated with the desired drug (10 mM gefitinib or
lapatinib) for 1 h at 37C. They were then incubated for 10 min at ambient
temperature with two-color labeled EGF (~300 pM Alexa Fluor 546 EGF
and Alexa Fluor 647 EGF) before imaging was conducted. Biotinylated
EGF-Streptavidin QD complexes at 500 nM final concentration were pre-
formed by incubation in TBS for 30 min on ice. The complex was diluted
with Optimem to a concentration of 1 nM and added to the live cells right
before imaging. All measurements in live cells were carried out in HEPES
(25 mM)-buffered Optimem at ambient temperature. Although a tempera-
ture of 37C for measurements would have been more similar to physiolog-
ical conditions, we performed the experiments at ambient temperature to
slow down the ligand-induced EGFR internalization process, which would
have rapidly depleted the membrane-bound receptor populations for our
total internal reflection fluorescence (TIRF)-based single-molecule mea-
surements. To enable quantitative single-molecule data analysis, room tem-
perature was chosen as an adequate alternative to 37C. However, all TKI
pretreatments were performed at 37C by incubation with 10 mM inhibitor
for 1 h under 5% CO2.
Measurements in fixed cells
Cells were cultured and seeded as described above on glass coverslips
placed in 24-well plates. Fluorescence immunostaining was performed
24 h after plating. Cells were stimulated with 100 ng/ml (~16 nM) EGF
for 15 min at 37C, chemically cross-linked with 4% paraformaldehyde
for 30 min on ice, and permeabilized with 0.4% Triton X-100 for 10 min
at room temperature. Samples were incubated overnight at 4C with fluo-
rescently labeled primary antibodies against EGFR (10 mg/mL) and
mounted in Mowiol or FluorSave (Calbiochem, UK) for FLIM and TIRF
microscopy (TIRFM) imaging, respectively.FLIM
Time-domain FLIM data were acquired via a time-correlated single photon
counting (TCSPC) custom-built, automated, open microscope (49). Briefly,
this consisted of a white-light supercontinuum laser (SC450; Fianium, UK)
for fluorescence excitation, a dual-axis scanner, a photomultiplier detector
(PMH-100; Becker and Hickl, UK) and SPC electronics (SPC830; Becker
and Hickl, UK). Images were acquired using an air 20 Plan Fluor objec-
tive (NA ¼ 0.50; Nikon Instruments, UK). Fluorescence lifetimes were
determined at every pixel using a modified Levenberg-Marquardt fitting
technique as described previously (50). The FLIM images were batch
analyzed by running an in-house exponential fitting algorithm (TRI2 soft-
ware) written in LabWindows/CVI (National Instruments, Austin, TX).
The fitting parameters for each time-resolved intensity imagewere recorded
in individual output files and used to generate a distribution of lifetime and
an average fluorescence lifetime. FLIM/FRET analysis was performed to
investigate protein-protein interactions (51–54). Using the donor lifetimes
only, FRET efficiencies were calculated based on the equation E ¼ 1 
tDA/tD, where tD and tDA are the measured fluorescence lifetimes of the
donor in the absence and presence of the acceptor, respectively.Single-molecule TIRFM
Single-molecule images were acquired using an objective-type TIRF setup
based on a Nikon Ti Eclipse microscope (Nikon Instruments, UK) equipped
with a 60, NA ¼ 1.49, Nikon TIRF objective. A continuous-wave, diode-
pumped, solid-state laser with emissions at 527 nm (DTL313; Laser2000,UK) and a 642 nm continuous-wave laser diode (Stradus Vortran;
Laser2000), respectively, were used as excitation sources and were coupled
to the microscope with free-space optics and a computer-driven positioner
(150-811ST; Thorlabs, UK) to control the TIRF angle. Fluorescence emis-
sion collected through the objective was split into two spectrally distinct
channels by passing it through a dichroic mirror (Semrock FF 665-Di02;
Semrock) and two band-pass filters (Bright Line 692/40 and 575/25; Sem-
rock). The two emission channels were simultaneously recorded at a rate
of 10 frames/s using an electron-multiplying charged-coupled device
(EMCCD) camera (Evolve 512; Photometrics, UK). The individual micro-
scope components were controlled using an in-house-written LabVIEW
(National Instruments, Austin, TX) program.
Emission of GFP-tagged cells was excited at 470 nm via an LED laser
diode (M470L2; Thorlabs), collected though the same objective, passed
through the Nikon FITC filter block (EX465-495, DM505), and detected
with a Nikon DS QiMc camera mounted on the back port of the microscope.
NIS-Elements software (Nikon Instruments, UK) was used to capture and
export the images in .tif format.Single-molecule data analysis
We performed multicolor single-molecule detection and tracking using pre-
viously described algorithms (52). Channel registration was extended to
include a cubic polynomial transformation between the channels. We de-
tected individual molecules using a single-channel feature detection algo-
rithm by comparing two models for the region of interest (ROI) around
each pixel. One model assumed that the image region around a pixel is
described by pure noise, H0 (background parameter B0). Alternatively,
when a molecule was present, the image region around a pixel was
described by a feature profile from a single point emitter within the pixel
plus background emission and stochastic noise, H1 (background parameter
B1, feature intensity I, feature coordinates x and y). Given a specific descrip-
tion for each pixel of the background emission, stochastic noise, and feature
profile, we calculated the probabilities for each model in each pixel using
Bayes’ theorem, a process known as Bayesian segmentation. In this
work, the feature profile given by the point spread function of the micro-
scope was approximated by a Gaussian profile with a fixed, known width.
The ROI considered around each pixel was a square with a side size of
approximately four times the assumed feature profile’s full width at half-
maximum intensity.
Fluorescence intensity time traces were generated using single proximity
tracking. A detected feature, i, detected in the first frame seeded subsequent
frames for which a connection probability that feature i belongs to track j
was calculated. Features were assigned to tracks, with at most one feature
per track and one track per feature based on the above calculated probabil-
ities. Features that were not assigned to existing tracks seeded new tracks
starting from the frame in which they were first detected. With the assump-
tion that features are more likely to be linked to tracks in the closest spatial
and temporal proximity, this method generates a set of tracks, each of which
corresponds to a time series of the detected molecule parameters (intensity,
x and y localization). Some tracks may exhibit missing frames due to blink-
ing or nondetected features. A simple method allows one to follow the
tracks through such gaps. We determined the position coordinates of each
detected feature with subpixel resolution by fitting the image of each mole-
cule to a two-dimensional Gaussian function.
We analyzed the extracted tracks for temporal coincidence using custom
software in LabVIEW. A homodimer was identified when the feature de-
tected in one channel was persistently located within 1 pixel (160 nm)
from a feature in the second channel. Single fluorophores were typically de-
tected with signal/noise ratio (SNR) y 8, for which we estimated an
average localization uncertainty of ~80 nm (Fig. S1 in the Supporting Ma-
terial). The separation distance between the two monomers detected in the
green and red channels, respectively (calculated as the Euclidian distance
between the (x, y) coordinates of the feature detected in the green and red
channels at the same time point t) was plotted as a function of time. ToBiophysical Journal 108(5) 1013–1026
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cation, more accurately determine the duration of a dimerization event, we
applied a five-point moving-average smoothing filter (10 frames/s). Addi-
tionally, tracks with more than four consecutive frames in which a molecule
was not detected were not included in the analysis, since the motion of the
molecules in such gaps is unknown. We found that gaps of fewer than four
time points allowed for fluorophore blinking and for the same molecule to
be picked up as it reappeared at the same location. The event duration was
measured in a similar manner as previously described (55). Dimer dissoci-
ation was marked by a transition in separation distance beyond the threshold
value of 160 nm (1 pixel). The average duration of the dimerization event,
ton, was determined by fitting an exponential decay to the histogram of
dimer association times using a Marquardt minimization algorithm. The
monoexponential function was defined as f (t) ¼ Z þ Aet/ton, where Z is
a baseline offset and A is the amplitude of the exponential function. Fitting
was performed with the baseline offset constraint to be positive. The error of
the decay, Dton, was determined from the Levenberg-Marquardt covariance
matrix as previously described (56). The dissociation rate koff was deter-
mined as 1/ton with the error Dkoff ¼ Dton/t2on. Correlated motion analysis
between pairwise single-molecule trajectories was performed as previously
described (24,57,58). The initial separation distance between two-color
EGFR trajectories was determined and if it fell below the specified
cutoff, the pair was further analyzed in sequential frames. To better describe
the receptor motion, we calculated two parameters: the magnitude of a re-
ceptor’s displacement (called the jump magnitude) and the extent of corre-
lated motion between nearby receptors (called the uncorrelated jump
distance). If two receptors formed a transient dimer, their diffusion would
be significantly reduced, which would show in a decrease in their jump
magnitude. Additionally, if two receptors formed a transient dimer, they
would move together, i.e., the motion of the two interacting receptors would
be correlated, producing a decrease in the uncorrelated jump distance. By
plotting the jump magnitude and the uncorrelated jump distance as a func-
tion of distance between receptor pairs, we can detect the presence of tran-
sient dimers, provided their lifetime is longer than the imaging acquisition
time.
To determine spFRET molecules, we used the multichannel feature
detection as described previously (27,59). In this case, a two-channel
feature was identified when a molecule was present at a particular location
in the green and/or red channels. Additional software filters were intro-
duced to ensure that the donor and acceptor time traces were at least
50% anticorrelated, no neighboring molecules were located within 1 pixel,
and the displacement during the measurement was less than 0.8 pixels.RESULTS
Enhanced EGFR homodimerization induced
by blocking tyrosine phosphorylation
To investigate the regulatory role of cytoplasmic autophos-
phorylation in EGFR signaling, we measured the average
fluorescence lifetime of EGF-bound receptor with and
without TKI pretreatment. EGFR was labeled with cyto-
plasmic Alexa Fluor 546 F-4 as donor (D) and DyLight
649 F-4 as acceptor (A). Fig. 1 a shows the intensity and
lifetime images of EGF-stimulated cells with and without
gefitinib pretreatment. Histograms of donor lifetimes in
the presence of acceptor for EGF-bound receptors with
and without gefitinib pretreatment were fitted to a monoex-
ponential, yielding tGefitinib þEGF
D,A ¼ 2.30 5 0.17 ns and
tEGF
D,A ¼ 2.46 5 0.19 ns, respectively. The errors are the
standard deviations determined for an individual measure-
ment averaged over five measurements. All of the ex-Biophysical Journal 108(5) 1013–1026perimentally determined parameters reported here were
statistically tested by paired t-test with a significance level
of 0.5. Gefitinib pretreatment was found to be associated
with a statistically significant reduction in lifetime (p <
0.001). Lapatinib-pretreated cells exhibited a fluorescence
lifetime of tLapatinib þEGF
D,A ¼ 2.47 5 0.15 ns, which
was not statistically significant from that of untreated con-
trol cells (data not shown). We note that gefitinib is known
to bind to the active kinase conformation of EGFR, whereas
lapatinib binds to the inactive kinase conformation of EGFR
and Her2. The different effects of gefitinib and lapatinib pre-
treatment are consistent with our previous findings in a
different cell model (34). Control experiments on donor-
only EGF-stimulated cells resulted in a fluorescence life-
time tEGF
D ¼ 2.49 5 0.14 ns.
The measured donor lifetimes were averaged over a het-
erogeneous mixture of species. We assumed that the donor
lifetime can be expressed as the sum of two subpopulations
of molecules (i ¼ 1, 2), where each of the subpopulations is
characterized by a specific lifetime, ti,, and amplitude, Ai.
The two subpopulations were represented by the noninter-
acting (monomer) and interacting (dimer) species, respec-
tively. Fluorescence lifetimes were determined by pixel
fitting or multi-image global fitting of the FRET/FLIM
data as previously described (60). Results of this analysis
are shown in Fig. 1 b. Lifetime t1 was determined by mono-
exponential multi-image global fitting of the D-only-labeled
cells to be 2.543 ns. The clear shift to lower lifetimes in the
presence of gefitinib indicates the occurrence of FRET and
hence increased dimer formation. The dimer lifetime, t2,
was calculated by biexponential multi-image global fitting
of the DA/gefitinib-treated cells, with t1 fixed to the previ-
ously determined value of 2.543, and A1 and A2 allowed
to vary freely. We calculated the fluorescence lifetime of
the gefitinib-treated homodimer as t2 ¼ 0.604 ns. After
determining the lifetimes of the noninteracting and interact-
ing species, we calculated their respective amplitudes Ai in
both gefitinib-treated and untreated samples by biexponen-
tial pixel fitting of the data with fixed parameters t1 ¼
2.543 ns and t2 ¼ 0.604 ns. Fitting was repeated for each
image in a set of five. The fraction or subpopulation of di-
mers was determined as A2/(A1 þ A2), where A1 and A2
are the previously determined fractions of monomer and
dimer, respectively. The subpopulation of EGFR homo-
dimers increased from 17% (0.174 5 0.006) to 24%
(0.244 5 0.029) with gefitinib treatment. The errors are
the standard deviation of the fractional intensity calculated
over the set of five images. The relative increase in homo-
dimerization with gefitinib pretreatment was found to be
statistically significant (p < 0.01). Equivalently, gefitinib
induced an ~41% shift in the contribution of interacting
species from a monomeric state toward a dimeric state, as
shown in Fig. 1 c.
The above interpretation is further supported by our ob-
servations at the single-molecule level. Ensemble FRET
FIGURE 1 Effect of gefitinib on EGFR homodimerization. (a) FRET/FLIM images of HCC1954 cells that were stimulated with EGF in the absence or
presence of gefitinib pretreatment, and then fixed and stained with Alexa 546- and Dy Light 649-labeled antibodies (clone F4) that recognize the intracellular
domain of EGFR. This corresponds to an increase in the apparent average FRETefficiency from 1.2% without gefitinib treatment (tEGF¼ 2.465 0. 19 ns) to
7.5% with gefitinib treatment (tgefitinibþEGF¼ 2.305 0.17 ns; p< 0.001). Fluorescence lifetimes were calculated by a monoexponential fit to the data. Scale
bar is 50 mm for all images. (b) Mono- and biexponential pixel fittings of the individual FRET/FLIM images of D-only-labeled cells (Alexa 546) and DA
(Alexa 546, Dy Light 649)-labeled cells before and after gefitinib treatment, respectively. (c) The partial contributions of the noninteracting, D-only-labeled
species and interacting DA-labeled species were deconvoluted and histograms of the EGFR homodimers subpopulations before (green) and after (red) ge-
fitinib treatment were plotted. Fractional-intensity histograms were accumulated over five images and normalized for direct comparison. The homodimer
percentage increased from 17% to 24% after the gefitinib treatment, which corresponds to ~40% enhanced dimerization. (d) Single-molecule signature
FRET images of an individual molecule. Single-molecule images of EGF-stimulated fixed cells fluorescently labeled with the Alexa Fluor 555/Alexa Fluor
647 D38-B1 FRET pair were acquired with dual-excitation TIRF (Fig. S2 b). At t¼ 3.7 s, only the acceptor emission can be detected. At t¼ 11.4 s, the donor
signal arises upon acceptor photobleaching. Scale bar is 1 mm for all images. (e) Corresponding spFRET track showing anticorrelated D and A signals
(E¼ 98%). A similar track was recorded for a gefitinib-pretreated molecule (E¼ 81%). (f) GFP fluorescence and donor FLIM images (of Alexa 546-labeled
anti-EGFR antibody) of fixed HCC1954 cells transfected with GFP cs DEP-1 (Alexa 546 tcsDEP-1¼ 2.695 0. 23 ns) and WT DEP-1 (Alexa 546 tWTDEP-1¼
2.455 0. 11 ns) plasmids for inactive and overexpressed DEP-1 (EGFR) phosphatase, respectively, without EGF stimulation. The apparent average FRET
efficiency increased from 3% for inactive DEP-1 phosphatase to 5% for overexpressed DEP-1 (p < 0.001). To see this figure in color, go online.
Fluorescence Imaging Analysis of EGFR Dimerization 1017measurements cannot distinguish whether the detected
signal arises from dimers or higher-order oligomers, or
detect heterogeneity in the distribution of FRETefficiencies.
When using a dye/protein stoichiometry of one, one can use
single-molecule methods to count the number of monomers
(61) using one color only, or spFRET (62), which can pro-
vide detailed structural information about the molecules of
interest. EGFR was tagged with the cytoplasmic antibody
D38-B1 fluorescently labeled stochastically with Alexa
Fluor 555 (D) and Alexa Fluor 647 (A). A detailed view
of a single molecule experiencing spFRET is shown inFig. 1 d. The corresponding fluorescence traces are plotted
in Fig. 1 e. As can be seen in Fig. 1, d and e, at earlier times
(3.7 s after the beginning of the measurement), a bright
fluorescent molecule can be observed in the acceptor (red)
channel, whereas there is no detectable signal at the same
location in the donor (green) channel. At later times
(11.4 s after the beginning of the measurement) and after
acceptor photobleaching, the acceptor can no longer be de-
tected in the red channel and the donor intensity increases in
the green channel. Changes in spFRET for a gefitinib-pre-
treated molecule are also shown in Fig. 1 d.Biophysical Journal 108(5) 1013–1026
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both multiple and single-step donor and/or acceptor photo-
bleaching events. Since the antibodies used for immunoflu-
orescence were stochastically labeled with dye per protein
ratios between 2 and 4, we cannot attribute the multiple pho-
tobleaching steps traces to genuinely formed oligomers.
However, single-step photobleaching traces demonstrate
the EGFR-EGFR interaction. For the particular examples
shown here (Fig. 1 d), we calculated spFRET efficiencies
upon acceptor photobleaching according to the equation
E¼ 1 – IDA/ID, where ID and IDA are the average donor fluo-
rescence intensities in the absence and presence of acceptor,
respectively. In contrast to calculations of FRET efficiency
using acceptor emission, spFRET efficiencies calculated
only from the donor emission do not need to be corrected
for leakage of the Alexa Fluor 555 signal into the Alexa
Fluor 647 channel, for direct excitation of Alexa Fluor
647, or for different quantum yields and quantum effi-
ciencies of the two fluorophores. The spFRET efficien-
cies for the individual traces were calculated to be 98%
(Fig. 1 d) and 81% (Fig. 1 e) for EGFR homodimers without
and with gefitinib pretreatment, respectively. These corre-
spond to D-A separation distances of ~25 A˚ and 40 A˚,
respectively, assuming randomly oriented fluorophores and
a 51 A˚ Fo¨rster radius for the FRET pair (Alexa Fluor 555,
Alexa Fluor 647 fluorescently labeled anticytoplasmic
EGFR antibodies). The measured distances are given as
direct evidence of homodimer formation. The lack of site-
specific dye labeling of the antibody prevented us from
determining the specific separation distances between the
EGFR monomers in these experiments. Assuming that
the fluorescently labeled cytoplasmic antibodies bind to
the two monomers in a TKD asymmetric dimer after
TKI treatment (35), we can only infer (from the short D-A
separation measured) that the antibodies’ binding sites
(epitopes) are located close to the dimerization interface.
Distance measurements based on the crystal structure of
the asymmetric active dimer conformation of the TKD as re-
ported by Protein Data Bank ID: 2JIU (20) have shown that
the distance between the two epitopes can be between 10 A˚
and >100 A˚ depending on their exact location.
The high spFRET efficiencies calculated for the examples
shown, together with the limited number of such observa-
tions we were able to make and the lower FRET efficiencies
measured in the ensemble, support the idea of a heteroge-
neous population comprised of a small subpopulation of
high-FRET-efficiency dimers and a majority of molecules
noninteracting on the FRET range scale. These structurally
different EGFR-EGF complexes may also account for
the different ligand binding affinities previously reported
(63,64).
Taking advantage of our previous finding that the EGFR-
interacting protein phosphatase DEP-1 decreases EGFR
phosphorylation and inhibits EGFR internalization and
downstream signaling, we investigated the effect of its over-Biophysical Journal 108(5) 1013–1026expression on the EGFR homodimerization level (45).
Successfully transfected cells were manually selected for
the analysis (Fig. 1 f). Surprisingly, similar values of the
fluorescence lifetime were measured for EGF-stimulated,
immobilized HCC1954 cells transfected with the GFP cs
DEP-1 (tEGF
csDEP-1 ¼ 2.55 5 0. 20 ns) and WT DEP-1
(tEGF
csDEP-1 ¼ 2.54 5 0. 22 ns), respectively, and stained
with the FRET pair (Alexa 546 and Cy5)-labeled intracel-
lular antibody Ab15 (EGFR). In contrast to TKI pretreat-
ment, when tyrosine phosphorylation was blocked before
EGF stimulation, overexpression of DEP-1 phosphatase
competed against the EGF stimulation and the two pro-
cesses could cancel out in the ensemble. However, perform-
ing the assay in nonstimulated cells induced a significant
(p < 0.001) drop in lifetime between the cells expressing
the inactive cs DEP-1 (tcsDEP-1¼ 2.695 0. 23 ns) and over-
expressing WT DEP-1 (tWTDEP-1 ¼ 2.45 5 0. 11 ns), as
shown in Fig. 1 f. To calculate the fraction of interacting spe-
cies (homodimers), we performed a fractional-intensities
analysis as previously described (60). Multi-image global
monoexponential fitting of the Alexa 546 donor-only-
stained cells transfected with the GFP cs DEP-1 plasmid
yielded a fluorescence lifetime t1 ¼ 2.74 ns. The fluores-
cence lifetime for the interacting species, t2, was derived
by multi-image global fitting of the two-color (Alexa 546,
Cy5) WT GFP-DEP1 transfected cells FRET/FLIM data
to a biexponential with t1 fixed to 2.74 ns. The fluorescence
lifetime of the interacting species was determined to be
0.74 ns. The fractional intensity of the homodimer in the
cs DEP-1 and WT DEP-1 transfected cells was derived
from the biexponential pixel fits of all five respective im-
ages, with t1 and t2 fixed to the previously determined
values. The fraction of homodimers in the cs DEP-1 trans-
fected cells was determined to be 16%. Overexpression of
DEP-1 phosphatase led to an increase in the fraction of ho-
modimers to 20% in the WT DEP-1 transfected cells. Like
gefitinib pretreatment, phosphatase overexpression facili-
tated dimer formation (with a 23% increase in the fraction
of dimers), reinforcing the positive correlation observed be-
tween receptor dimerization and a dephosphorylated state.Two-color detection of EGFR dissociation and
off-rate measurement in the plasma membrane
One possible explanation for the macroscopically measured
increase in EGFR dimer formation in response to gefitinib
treatment is the prolonged duration of homodimerization
events in live breast cancer cells after pretreatment with ge-
fitinib. Single-molecule methods have the ability to capture
the dimerization process in real time and allow us to derive
the receptor reaction kinetics and effect of gefitinib on the
dissociation rate of the homodimer.
Endogenous association/dissociation events of EGFR re-
ceptors were observed in real time (10 frames/s) on the
membrane of live HCC1954 cells that were provided with
Fluorescence Imaging Analysis of EGFR Dimerization 1019a mixture of EGF fluorescently labeled with two spectrally
different fluorophores and allowed to bind their ligand. In a
previous study, it was reported that fluorescent labeling of
the N-terminal amino group of EGF did not to interfere
with individual receptor dynamics (27). Here, single fluoro-
phores were typically detected with an SNRy 8, for which
we estimated an average localization uncertainty of ~80 nm
(Fig. S1 f). Individual Alexa Fluor 546 EGF- and Atto 647
EGF-bound receptors diffusing on the plasma membrane
were detected in the green and red channels, as illustrated
in Fig. S2 a by the green and red spots, respectively. The
green and red molecules located within one pixel
(160 nm) of each other were considered to be colocalized
in space and selected for koff derivation.
The EGFR homodimer off-rates were determined from
repeated individual experiments for specific conditions
(Table S2). The histogram of dimer lifetimes shown in
Fig. 2 a summarizes the two-color data for EGF-bound re-
ceptors acquired in a total of five individual experiments
on more than 2000 dimerization events. A dissociation con-
stant koff
EGF ¼ 1.19 5 0.05 s1 was determined by fitting
the distribution of lifetimes to a single exponential (55).
The koff derivation was performed as follows: First, fluo-
rescence intensities were used to detect two molecules. One
molecule was labeled with Alexa Fluor 546 (green) and
its dimerization partner was tagged with Atto 647 (red).
Fig. 2 b shows full-time fluorescence traces of a pair of mol-
ecules that colocalized during the acquisition time. The
duration of fluorescence emission for the full track length
was compared with the duration of fluorescence for the
length of the colocalized tracks. Full tracks that started orthe duration of the dimerization event, the separation distance remains under the
dissociation. This allows us to extract the apparent duration of an individual dim
provides the ton for the EGFR homodimer and the corresponding dissociation rended with simultaneous emission in the green and red
channels or colocalized for the entire acquisition time
were excluded from the analysis because the start and/or
end of the dimerization event could not be clearly
determined.
The molecules were tracked for the duration of the mea-
surement and their x and y coordinates were recorded. If the
duration of the encounter was longer than 500 ms (five
frames, i.e., the time during which the two molecules
were within one pixel (160 nm) of each other), a dimeriza-
tion event was deemed to have occurred. The duration of a
single dimerization event or the lifetime of an individual
dimer, ton, was determined using the spatial and temporal
information collected for a pair of colocalized molecules.
Dimer events with durations between 0.5 s and 6 s were de-
tected and included in the fit of the histogram. Fig. 2 c shows
the variation in x and y coordinates for the two molecules
during the time they were detected in the two channels (be-
tween 0 and 12 s from the beginning of the acquisition).
Changes in the separation distance between the two mole-
cules as a function of time are plotted in Fig. 2 d. As one
of the molecules diffused away, the EGFR dimer dissociated
and the separation distance increased abruptly above the
threshold (Fig. 2 d). The 160 nm cutoff was empirically
found to be the most robust given the SNR for our data. A
variable dimerization cutoff value based on the localization
uncertainty of individual pairs of colocalized molecules was
also tested. However, this criterion was found to be less
robust in the case of noisier data (larger localization uncer-
tainties) when unwanted events were included in the anal-
ysis. The large cutoff value is comparable to the size ofFIGURE 2 Kinetic analysis of EGFR homo-
dimer dissociation. (a) Distribution of EGFR ho-
modimer lifetimes after EGF stimulation for all
accumulated data acquired in five individual ex-
periments employing various TKIs (gefitinib,
lapatinib, and AZD 8931). The distribution of
more than 2000 dimerization events was fitted
to a monoexponential where kapp
EGF ¼ 1.19 5
0.05 s1. (b) Two-color fluorescence emission cor-
responding to a pair of colocalized molecules
labeled with Alexa Fluor 546 (green) and Atto
647 (red), respectively. (c) Changes with time of
the horizontal and vertical positions of the dimer-
ization partners. The two molecules temporally
coexist between ~0 and 12 s from the beginning
of the measurement. Dimer formation implies
simultaneous detection of both molecules at the
same time (temporal colocalization) and same
location (spatial colocalization). The horizontal
and vertical feature positions report on the mole-
cules’ spatial colocalization. (d) The separation
distance between the two-color monomers in prox-
imity to each other decreases below the threshold
and marks the start of the dimerization event. For
threshold, followed by a stepwise increase above the threshold upon dimer
erization event, tapp. The photobleaching corrected colocalization duration
ate koff. To see this figure in color, go online.
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1020 Coban et al.lipid raft nanodomains where receptors may be coconfined,
but the existence of homodimeric rafts is very transient with
lifetimes below our temporal resolution of 10 frames/s. The
probability of tracking incidental colocalization or codiffu-
sion for multiple frames is small. Our observations revealed
spatial and temporal colocalization that was longer than the
incidental colocalization but shorter than the time to photo-
bleaching, indicating a higher likelihood that we mostly
observed bona fide dimers (65). We also note that the
average track lengths we measured were more than 10 times
longer than the association times, which eliminates any con-
cerns regarding molecule disappearance due to photo-
bleaching on the timescale of the dimerization events. The
photobleaching lifetimes for the fluorescent probes used
were determined from the track lengths of the individual flu-
orophores in single-molecule colocalization experiments.
The experimentally determined times to photobleaching
were consistent with previously estimated values for sin-
gle-molecule experiments (66). The decay constants were
corrected for photobleaching as described elsewhere (67),
providing the true colocalization duration and rates (Table
S1). To further confirm the presence of EGFR dimers, we
performed additional data analysis to determine the degree
of correlated motion, as described briefly in Materials and
Methods and elsewhere (24,58). We observed that theFIGURE 3 Single-molecule analysis of the effect of the TKI gefitinib on the
ization events fitted to a single exponential with koff
EGF ¼ 1.105 0.07 s1 and
(c and d) Ensemble correlated motion analysis of two-color single-particle track
pretreatment, respectively, for all two-color tracked molecules. The average rec
plotted as function of the separation distance. Correlated motion at small separat
can be seen by the decrease in the uncorrelated jump distance (blue) when the tw
the jump magnitude (red). Decreased mobility with dimerization (i.e., a drop in
treatment. (e) Dissociation rates calculated from five individual experiments sho
dently of the type of TKI used (lapatinib, gefitinib, or AG 1478). (f) Decreased sa
molecules shifted from 3.59%5 1.56% to 1.95%5 0.63% after gefitinib pret
Biophysical Journal 108(5) 1013–1026magnitude of the uncorrelated jump distance for receptor
pairs decreased as the receptors were in close proximity
(Fig. 3 c, blue line), consistent with the formation of dimers.
The jump size also decreased at small separation distances
(Fig. 3 c, red line), but not to the same extent as the uncor-
related jump distance, further supporting the notion that the
effect is due to dimerization and not merely coconfinement.
In this study, we preferred to use small organic fluorophores
and take advantage of their photophysical characteristics,
which allowed us to perform ensemble FRET/FLIM mea-
surements on the endogenous receptor.ATP-competitive, small-molecule TKIs stabilize
the EGFR dimer
We further used our single-molecule assay to assess the
effect of various small-molecule TKIs (i.e., gefitinib,
AG1478, and lapatinib) on EGFR homodimerization.
TKIs compete with ATP for binding to the EGFR intracel-
lular TK domain. Untreated and TKI-pretreated cells were
incubated with picomolar concentrations of two-color
EGF and imaged by TIRFM. Data were acquired from 20
different areas per experiment, with two to six cells in the
field of view. The monoexponential fits of the EGFR homo-
dimer lifetimes determined from an individual experimentEGFR homodimer stability. (a and b) Histograms of the duration of dimer-
Koff
gefitþEGF ¼ 0.875 0.09 s1 when cells were pretreated with gefitinib.
ing data for EGF-stimulated cells in the absence and presence of gefitinib
eptor displacement (red) and the degree of uncorrelated motion (blue) are
ion distances indicates dimerization. Increased correlation at short distances
o receptors approach one another. The diffusion behavior was monitored via
jump magnitude at short distances) was observed independently of gefitinib
w a consistent reduction in koff (p < 0.05) with TKI pretreatment indepen-
mple heterogeneity after gefitinib pretreatment. The fraction of colocalized
reatment. To see this figure in color, go online.
Fluorescence Imaging Analysis of EGFR Dimerization 1021are displayed in Fig. 3, a (nontreated cells) and b (gefitinib-
treated cells). The measured EGFR dimer off-rates were koff
EGF alone ¼ 1.10 5 0.07 s1 (1294 dimerization events)
and koff
gefitþEGF ¼ 0.87 5 0.09 s1 (634 dimerization
events) in the absence and presence of gefitinib treatment,
respectively.
Dimerization was again confirmed by correlated motion
analysis (Fig. 3 d). The observed decrease in the uncorre-
lated jump distance at small separations demonstrates the
presence of dimers in both untreated (Fig. 3 c) and gefiti-
nib-treated (Fig. 3 d) cells.
The off-rates derived from five individual paired ex-
periments are shown in Fig. 3 e. Consistent trends were
observed in repeat experiments, regardless of which TKI
was used. The dissociation rates, averaged over these
five experiments (lapatinib and gefitinib were each used in
two independent experiments and AG1478 was used in
one experiment), decreased from koff
EGF alone ¼ 1.22 5
0.20 s1 to koff
TKIþEGF ¼ 0.95 5 0.07 s1 with TKI pre-
treatment (p < 0.05).
An additional parameter we measured was the fraction of
colocalized molecules. Fig. 3 d shows the distribution of the
percentage of detected dimers in the experiments described
above. The fraction of gefitinib-pretreated dimers displayed
a reduced variance of 1.95% 5 0.63% versus 3.59% 5
1.56% for the untreated sample, consistent with the reduc-
tion in koff.
Simulations were performed with parameters set to the
experimentally determined values for intensity, background,
photobleaching rate, and diffusion coefficient. Colocaliza-
tion analysis of thousands of simulated single molecules,
similar to the number of molecules tracked in a typical
experiment, resulted in only ~0.2% colocalized molecules,
which is significantly below the experimentally observed
colocalization rates (Fig. 3 f). Only five molecules were
found to coincidentally colocalize in time and space,
compared with more than 300 in a real experiment.Effect of an inhibitory anti-EGFR scFv
on the receptor homodimerization
A different class of EGFR inhibitors is represented by
monoclonal antibodies that block ligand binding. To inves-
tigate whether this EGFR-inhibiting strategy has the same
stabilizing effect on the EGFR homodimer (Fig. S3), we em-
ployed a dual-labeled 425 Snap (scFv) anti-EGFR devel-
oped in a previous study (48). The 425 Snap (scFv) can be
used to detect receptor dimerization, but does not trigger
downstream effector phosphorylation as probed by Western
blotting (Fig. S3 b). Similarly, pretreatment with TKIs (ge-
fitinib and lapatinib) was shown to inhibit receptor phos-
phorylation (Fig. S4). Dimerization of 425 Snap (scFv)
was observed with one-color single-molecule detection
(Fig. S3 d) and the off-rates of the nonliganded receptors
were determined using the two-color assay described above.EGF and 425 Snap (scFv) differed significantly in the per-
centage of colocalized single-molecule tracks (Fig. S3 f).
The largest percentage of dimers per cell (2.59% 5
0.70%) was detected for EGF-mediated activation. When
a combination of EGF and scFv ligands was used, the per-
centage of homodimers decreased to 1.01% 5 0.34%,
with the lowest fraction of dimers recorded for scFv ligand
only (0.40%5 0.34%). Experiments with all three ligands
were performed on the same day, thus eliminating day-to-
day variability. A consistent shift with the same trend was
registered in repeated experiments.
We calculated the dissociation rates for the molecules that
dimerized when scFv or EGF and scFv were used as ligands.
From repeated experiments, we calculated the mean dissoci-
ation rates of koff
EGF&scFv ¼ 1.425 0.16 s1 (2798 dimer-
ization events) and koff
scFv ¼ 1.02 5 0.45 s1 (1869
dimerization events), where the errors represent the
mean5 SE. Statistical analysis did not show any significant
difference compared with EGF. Our results suggest there is
no significant difference between the dissociation constants
of EGFR homodimers with 1) double-ligand EGF
occupancy, 2) asymmetric dimers of one ligand-bound
monomer and one 425 scFv bound receptor, and 3) double
425 scFV ligated dimers.
We concluded that gefitinib pretreatment yielded a more
stable EGF-bound EGFR dimer, whereas the scFv inhibitor
did not exert any measurable effect. Both classes of inhibi-
tors (TKIs and 425 scFv) resulted in a lower density of di-
mers on the cell surface and reduced heterogeneity (Figs.
2 f and S2 f). We note that the reduced probability of
observing dimers when using 425 scFv (EGFR) as a ligand
(Fig. S2 f) significantly limited our ability to determine
the various off-rates. Additionally, 425 scFv may induce
extracellular conformational changes that through the
coupling of extra- and intracellular domains may affect
EGFR homodimerization.Tyrosine phosphatase overexpression stabilizes
the EGFR dimer
An alternative negative-feedback mechanism for regulating
downstreamsignalingofEGFR is receptor dephosphorylation
(68,69). We previously showed that the EGFR-interacting
protein phosphatase DEP-1 decreases EGFR phosphorylation
and inhibits EGFR internalization and downstream signaling
(45). We determined the off-rates of EGF-stimulated dimers
in inactive versus overexpressed GFP phosphatase DEP-1 in
HCC1954 cells via single-molecule imaging to further char-
acterize the role of phosphorylation in EGFR stability.
Cells expressing the GFP DEP-1 construct were identified
via GFP fluorescence excited with 470 nm light. Fig. 4, a
and d, respectively, show transmitted bright-field illumina-
tion and 470 nm excited epifluorescence images of live
cells transfected with WT DEP-1 and inactive cs DEP-1.
Bright-field images show all of the cells present in the fieldBiophysical Journal 108(5) 1013–1026
FIGURE 4 Overexpression of EGFR-targeted
GFP DEP-1 phosphatase stabilized the EGFR ho-
modimer. (a) Bright-field trans illumination (left)
and epifluorescence (right) images show live cells
and GFP fluorescence of the corresponding GFP
WT DEP-1-transfected cell under 470 nm excita-
tion. (b) Histograms of the durations of dimerization
events for GFP WT DEP-1 in live HCC1954 cells.
A monoexponential fit of the histogram yielded
the off-rates koff
WTDEP-1 ¼ 1.12 5 0.16 s1
(382 events). (c) Ensemble correlated motion anal-
ysis for two-color EGF-treated HCC1954 cells
overexpressing GFP WT DEP-1 phosphatase.
Correlated motion at short distance can be visual-
ized through the decrease in uncorrelated jump
distance (blue). The concurrent drop in jump
magnitude (red) indicates decreased diffusion for
the homodimer. (d–f) Corresponding data for the
GFP cs DEP-1 inactive phosphatase control experi-
ment. The dimer off-rate was koff
csDEP-1 ¼ 1.815
0.33 s1 (248 events). To see this figure in color,
go online.
1022 Coban et al.of view. Only the GFP-transfected cells can be visualized in
the corresponding epifluorescence image. GFP detection
enabled us to select only the phosphatase DEP-1-transfected
cells for data acquisition. The dissociation constants were
derived as described above and the results are summarized
in Table S2. Distribution of the homodimer lifetimes in cells
expressing the WT and cs DEP-1 (EGFR) plasmids were
fitted to a monoexponential as shown in Fig. 4, b and e,
respectively. In the presence of cs DEP-1, the EGFR off-
rate increased from koff
EGF,WTDEP-1 ¼ 1.12 5 0.16 s1 to
koff
EGF,csDEP-1¼ 1.815 0.33 s1. Thus, EGFR dephosphor-
ylation also has a stabilizing effect on the EGFR ho-
modimer, similar to that observed for TKIs. Ensemble
correlated motion analysis again demonstrated a decrease
in uncorrelated motion and diffusion at small separations
(Fig. 4, c and f).The cellular proliferative response to gefitinib
depends on its ability to dimerize
We postulated that the TKI-associated change in the EGFR
homodimer kinetics could directly impact the signaling
property of the EGFR signaling network on the plasma
membrane and hence the proliferative activity of the breast
tumor cells. The current models for intracellular EGFR ho-
modimerization suggest the formation of an asymmetric
dimer between the C-terminal lobe of one kinase domain
(which acts as the activator) and the N-terminal lobe of
another kinase domain (which acts as the receiver)Biophysical Journal 108(5) 1013–1026(13,70,71). To test our hypothesis that the gefitinib-induced
EGFR dimer may affect cell proliferative function, we stud-
ied the effect of gefitinib on the proliferation of HCC1954
cells expressing the WT and (I706Q, V948R) ErbB1 plas-
mids. In a recent study, we showed that the EGFR I706Q,
V948R mutation perturbs the ability of EGFR to dimerize
to another ErbB partner, ErbB4 (47). HCC1954 (which co-
expresses both EGFR and HER2) was previously shown to
be prone to developing resistance to EGFR/HER2 inhibition
(72). The dose-response proliferation curve after 96 h of ge-
fitinib treatment is shown in Fig. 5. Above 300 nM, gefitinib
was shown to increase the proliferation of HCC1954 trans-
fected with WT EGFR. Sensitivity to gefitinib (i.e., sup-
pression of proliferation) was restored by expressing the
dimerization-incompetent EGFR mutant.DISCUSSION
Although recent studies have provided extensive information
about the allosteric conformational change of EGFR that is
induced by growth factor stimulation (3–7), and the use of
single-molecule binding kinetics to monitor conformational
changes in proteins is fairly well established (8), the effects
of clinically used, targeted therapies against EGFR are only
beginning to be understood (9,73). Furthermore, the advent
of next-generation sequencing (NGS) (74) has revealed
genetic mutations that are widely heterogeneous among
tumor subclones, even within the same patient tumor
(75,76). The use of quantitative, single-molecule-based
FIGURE 5 HCC1954 cells were treated for 96 h with a range of gefitinib
concentrations and proliferation was measured using an Alamar Blue assay
(Life Sciences). Cells were transfected with WT and I706Q/V948R ErbB1
24 h before treatment. Plotted are the means 5 SE of a triplicate experi-
ment. Data were normalized to control (untreated cells).
Fluorescence Imaging Analysis of EGFR Dimerization 1023imaging techniques to probe the effects of drug treatment on
EGFR will complement the NGS approach by providing a
functional readout that can potentially detect genetic variants
(of different allelic fractions) that break through as the tumor
subclones evolve.
The TKI gefitinib inhibits growth in some tumor types by
targeting EGFR. Recurrent somatic activating mutations
that occur in the exons encoding the kinase domain of
EGFR have been reported to respond clinically to gefitinib
(77–79). However, most patients who respond to therapy ul-
timately develop disease progression within 9–14 months of
treatment. This particular aspect of receptor biology is very
much in need of further elucidation within the ErbB thera-
peutic field, to improve our understanding of the heteroge-
neity in treatment response and ultimately to improve the
efficacy of treatment for cancer patients.
Here, we have shown the effect of clinically used EGFR-
targeted inhibitors (gefitinib and lapatinib) on the EGFR ho-
modimerization kinetics in a basal-like breast cancer cell
line, HCC1954. Gefitinib was shown to modulate EGFR ho-
modimerization at the single-molecule level via a 25% in-
crease in the duration of a homodimer in the presence of
the drug. The stability conferred by gefitinib binding allows
EGFR to form a higher fraction of homodimers. FRET/
FLIM measurements showed a 40% increase in the fraction
of homodimers in gefitinib-treated cells compared with non-
treated cells. The ability of gefitinib to modulate EGFR
homodimerization is likely to be important for cellular
signaling. HCC1954 (which coexpresses both EGFR and
HER2) was previously shown to be prone to developing
resistance to EGFR/HER2 inhibition (72). The addition of
gefitinib to WT EGFR at a concentration above 300 nM
was shown to enhance cell proliferation, contrary to the in-
tended role of TKIs. Sensitivity to gefitinib was restoredwhen we used a double-site, dimerization-deficient EGFR
mutant (the aforementioned EGFR I706Q, V948R mutation,
which perturbs the ability of EGFR to dimerize through
either the C-lobe (activator) or N-lobe (receiver) (47)).
This suggests that the modest drug-induced increase in sta-
bility of the EGFR homodimer may have a significant bio-
logical impact on the tumor cell’s proliferation potential.
Small ATP-competitive inhibitors specifically inhibit kinase
activity by binding to the ATP-binding sites situated in the
cytoplasmic domain of EGFR. However, the effect on the
dissociation constant, percentage of homodimers, and
cellular proliferation is not universal for all inhibitors and
must be interpreted in the context of drug-bound receptor
conformation. In the case of type I inhibitors such as gefiti-
nib, the crystal structure (Protein Data Bank ID 2ITY)
shows that the drug stabilizes the active EGFR conformation
(as defined by the model of an active, asymmetric, head-to-
tail EGFR homodimer (80)). Upon gefitinib pretreatment,
catalytically incompetent quasi-dimers are formed (34). La-
patinib, which is a type II inhibitor, stabilizes the inactive
EGFR conformation. We found that the observed effect of
lapatinib on the homodimer stoichiometry and dissociation
constant was not statistically significant (data not shown).
This is similar to another EGFR TKI, PD153035, which
was previously reported to have no effect on the ligand-
bound EGFR homodimer off-rates (24). However, no crys-
tallographic structure of the PD153035-bound receptor is
currently available for comparison with that of gefitinib/
lapatinib.
The overall architecture of the ErbB pathway, which has
been described as a bow-tie (or hourglass)-shaped structure
with several feedback loops (81,82), is most likely to be the
basis for the amplification of the modest drug-induced in-
crease in stability of the EGFR homodimer. Also, previous
single-molecule studies have shown that dynamic lateral in-
teractions among EGFR receptors on the plasma membrane
induce amplification of EGFR signaling (83). This is consis-
tent with our observation that a small change in the duration
of the homodimer with gefitinib treatment resulted in a sig-
nificant increase in the fraction of asymmetric, unphos-
phorylated receptor homodimers. This is in addition to the
link we have shown between the ability of EGFR to undergo
dimerization and the impact of gefitinib on tumor cell pro-
liferation. Similarly, a small change in the duration of an
EGFR-containing heterodimer can result in a large down-
stream effect. As an example, a similar amplification effect
was recently observed for the EGFR-ErbB4 heterodimer
(47). The effect of dimer-perturbing mutations (including
the I706Q, V948R double mutation of EGFR used in this
study) on the heterodimer off-rate was modest (~33% in-
crease), but resulted in the abrogation of growth factor-stim-
ulated cell migration.
The inhibitory 425 SNAP (scFv), which can block endog-
enous EGF binding, caused a reduction in the percentage
of EGFR single-molecule tracks that colocalized. For theBiophysical Journal 108(5) 1013–1026
1024 Coban et al.dimers that did manage to form, however, the off-rate was
not significantly different from that observed with the natu-
ral ligand EGF. This is different from the unliganded EGFR
homodimer, which was found to have a >4-fold faster koff,
as detected by the camelid variable fragment of heavy chain
antibody, which does not compete for EGF binding (24).
The difference between the different antibodies may be ac-
counted for by the different receptor conformations these
antibodies can stabilize (according to the effect on EGF
binding), similar to the case of the different TKIs described
above. Up to 90% of the dimers formed when scFVonly was
used as ligand were inactive and would be most likely be
represented by a symmetric TKD. The similar dissociation
rates measured for EGF- and scFv-induced dimers suggest
that both symmetric and asymmetric TK interfaces are
equally able to stabilize the intracellular part of the dimer.
In the case of overexpressed DEP-1 tyrosine phosphatase,
the levels of EGFR phosphorylation are determined by the
balance between the receptor TK and phosphatase activities.
The increase in apparent FRET efficiency in cells overex-
pressing phosphatase could only be observed in the absence
of EGF stimulation. The increased homodimer stability with
phosphatase overexpression could be observed in single-
molecule experiments performed in the presence of picomo-
lar concentrations of the ligand, an order of magnitude
below the concentration used in ensemble measurements.
Cells overexpressing EGFR-specific TK DEP-1 phospha-
tase showed increased dimer stability (koff
WTDEP-1 ¼ 1.12
5 0.16 s1) as compared with EGFR receptor homodimers
in cells transfected with the inactive DEP-1 phosphatase
(koff
csDEP-1 ¼ 1.81 5 0.33 s1). The measured difference
between the dissociation rate of the phosphorylated and de-
phosphorylated EGFR homodimers may be attributed to
different conformations of the phosphorylated versus non-
phosphorylated receptor.
We also show some examples of spFRET recorded on
EGFR homodimers stained with donor and acceptor cyto-
plasmic antibody D38-B1 with and without TKI pretreat-
ment (Fig. 1, d and e). spFRET was visualized via donor
recovery after acceptor photobleaching in fixed HCC1954
cells. Detection of spFRET demonstrates direct interaction
of the individual monomers, providing further support for
the conclusion that our single-molecule results from live
cells (with or without TKI) report on bona fide complexes
rather than two molecules coconfined within a diffraction-
limited spot. However, quantification of the spFRET is
beyond of the scope of this work.
Previous studies (84,85) showed that when EGFR phos-
phorylation was prevented by cytoplasmic mutations, the
dimer’s binding affinity for ligand was higher than that pre-
dicted by a ligand-induced dimerization model. Our single-
molecule data extend that observation by demonstrating
directly that the stability of the EGFR homodimer is sen-
sitive to the phosphorylation state of the receptor. A re-
cent study also noted the correlation between suppressedBiophysical Journal 108(5) 1013–1026EGFR autophosphorylation on specific binding sites (Grb2
and c-Cbl) and receptor stability and sustained signaling
(47,86). Taken together, our observations (obtained using
TKIs and phosphatase expression) provide support for the
idea proposed in other reports that there are conformational
differences between the phosphorylated and unphosphory-
lated forms of the receptor.SUPPORTING MATERIAL
SupportingMaterials andMethods, Supporting Results, four figures, and two
tables are available at http://www.biophysj.org/biophysj/supplemental/
S0006-3495(15)00066-1.
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